In Hong Kong on September 15, 2025, Akeso, Inc. (9926.HK) disclosed the initiation of dosing for the initial patient in its worldwide, multi-location, randomized Phase II registrational study named COMPASSION-36/AK104-225. This trial marks the investigation of cadonilimab, a product of Akeso, aimed at assessing its efficacy and safety.
